Which JAK inhibitors are approved in the U.S?
There are currently 11 Janus kinase (JAK) inhibitors approved by the U.S. Food and Drug Administration (FDA). The most recent approval was Leqselvi (deuruxolitinib) on July 25, 2024. The first JAK inhibitor approved in the U.S. was Jakafi (ruxolitinib) on Nov. 16, 2011.
Related: Table of Approved U.S. JAK Inhibitors
What is a JAK Inhibitor?
Janus kinase (JAK) inhibitors are a group of medications that block immune system proteins in the body that often lead to inflammation and pain. JAKs help the immune system communicate with each other, but when JAK enzymes (such as JAK1, JAK2, JAK3, and TYK2) are blocked in the cell, this can help to lower overactivity of the immune system.
JAKs inhibitors are approved to treat of a variety medical conditions, including rheumatoid arthritis, atopic dermatitis (eczema), COVID-19, and certain rare blood cancers of the bone marrow (myelofibrosis).
When used for the treatment of rheumatoid arthritis or psoriatic arthritis, JAK inhibitors are part of a larger group of drugs called Disease-Modifying Anti-Rheumatic Drugs (DMARDs). DMARDs help to slow down ongoing, permanent joint or tissue damage in these conditions. They may be used when other more conventional treatments have not worked or were not tolerated.
Risks of JAK inhibitors include serious or even life-threatening side effects, like infections, cancer, heart attacks or blood clots, so they are not typically used as an initial treatment. Talk to your doctor about the side effects you can expect with the JAK inhibitor you are using.
JAK inhibitors come in oral and topical (skin) formulations and are typically administered once or twice daily.
Table of JAK Inhibitors Approved in the United States
| Drug | Indications | Usual Administration | Initial FDA Approval Date | Manufacturer |
|
Cibinqo (abrocitinib) JAK1 inhibitor |
|
Oral tablets
Once daily |
January 14, 2022 | Pfizer Inc. |
|
Inrebic (fedratinib)
JAK2 inhibitor |
|
Oral capsules
Once daily |
August 16, 2019 | Bristol-Myers Squibb Company |
|
Jakafi (ruxolitinib)
JAK 1 / 2 inhibitor |
|
Oral tablets
Twice daily |
November 16, 2011 | Incyte Corporation |
|
Litfulo (ritlecitinib) AK3 and TEC (tyrosine kinase expressed in hepatocellular carcinoma) inhibitor |
|
Oral capsules
Once daily |
June 23, 2023 | Pfizer Inc. |
|
Leqselvi (deuruxolitinib) JAK1 and JAK2 pathways |
|
Oral tablets
Twice daily |
July 25, 2024 | Sun Pharma |
|
Ojjaara (momelotinib)
JAK1 / JAK2 and activin A receptor type 1 (ACVR1) inhibitor |
|
Oral tablets
Once daily |
September 15, 2023 | GSK |
|
Olumiant (baricitinib)
JAK inhibitor (greater inhibitory potency at JAK1, JAK2 and TYK2 relative to JAK3) |
|
Oral tablets
Once daily In COVID-19, given for up to 14 days, or until hospital discharge, whichever is first. |
May 31, 2018 | Eli Lilly and Company |
|
Opzelura (ruxolitinib)
JAK 1 / 2 inhibitor |
|
Topical cream
Apply twice daily |
September 21, 2021 | Incyte Pharmaceuticals |
|
Rinvoq, Rinvoq LQ (upadacitinib) JAK inhibitor |
|
Oral tablets, extended-release, oral solution
Once daily (tablets) Twice daily (solution) Rinvoq LQ oral solution is not substitutable with Rinvoq extended-release tablets. Changes should be made only by |
August 16, 2019 | AbbVie Inc. |
|
Vonjo (pacritinib)
JAK2 / FLT3 / IRAK1 inhibitor
|
|
Oral capsules
Twice daily |
February 28, 2022 | CTI BioPharma Corp. |
|
Xeljanz, Xeljanz XR (tofacitinib)
JAK inhibitor |
|
Oral tablets, immediate-release - usually given twice daily.
Oral tablets, extended-release - usually given once daily. Oral solution - usually given twice daily. |
November 6, 2012 | Pfizer Inc. |
Related questions
- What are the new drugs for rheumatoid arthritis (RA)?
- What are JAK inhibitors and how do they work?
- Litfulo vs Olumiant: How do they compare?
Related
This is not all the information you need to know about JAK inhibitors for safe and effective use and does not take the place of your doctor’s directions. Review the full product information and discuss this information and any questions you have with your doctor or other health care provider.
References
- Fact Sheet for Healthcare Providers - Emergency Use Authorization (EUA) of baricitinib. Eli Lilly & Co. Indianapolis, IN. Revised May 2022. Accessed July 16, 2025 at https://pi.lilly.com/eua/baricitinib-eua-factsheet-hcp.pdf
- Opzelura (ruxolitinib) cream. Prescribing information. Incyte. Wilmington, DE. Revised 8/2024. Accessed July 16, 2025 at https://www.opzelura.com/opzelura-prescribing-information
Read next
How effective is Olumiant for Alopecia Areata (hair loss)?
In studies, about 17% to 35% of adults with severe alopecia areata achieved an 80% or greater scalp hair coverage at 36 weeks, as well as eyebrow and eyelash regrowth, depending upon their Olumiant dose. Some patients using the higher 4 mg dose saw 80% scalp hair regrowth at 24 weeks. Continue reading
How effective is Litfulo for hair loss (alopecia)?
About 1 in 4 patients will see hair regrowth covering at least 80% of their scalp within 6 months of taking Litfulo daily. Around 13% of patients taking Litfulo will have at least 90% of scalp coverage after 24 weeks. Continue reading
What happens when you stop taking Xeljanz?
Stopping treatment with Xeljanz may cause the symptoms of your condition to return. However, some patients are able to stop Xeljanz without their symptoms flaring up, according to the results of research conducted in patients with rheumatoid arthritis. You should not stop taking Xeljanz without consulting your doctor. Continue reading
See also:
Related medical questions
- Is baricitinib (Olumiant) being used to treat COVID-19?
- What type of drug is Olumiant (baricitinib)?
- How long does Xeljanz take to work?
- Does Xeljanz cause hair loss?
- What is Xeljanz used for and is it a biologic?
- Can I drink alcohol while taking Xeljanz?
- Is Xeljanz an immunosuppressant?
- Does Xeljanz cause weight gain?
- Can you take Xeljanz with antibiotics and antifungals?
- Does Xeljanz cause high blood pressure?
- Who makes Xeljanz and where is it made?
- Is Xeljanz approved for ankylosing spondylitis?
- What are the most common skin conditions? (with photos)
- Rinvoq Copay Card: Do I qualify and how much can I save?
- What is the MOA and half-life for Rinvoq?
- How long does Rinvoq stay in your system?
Related support groups
- Olumiant (7 questions, 4 members)
- Litfulo (4 questions, 4 members)
- Xeljanz (21 questions, 38 members)
- Rinvoq (8 questions, 11 members)
- Xeljanz XR (7 questions, 7 members)
- Jakafi (5 questions, 21 members)
- Opzelura (3 questions, 3 members)
- Cibinqo (3 questions, 3 members)
- Vonjo (2 questions, 3 members)
- Inrebic (2 questions, 3 members)
- Ojjaara (2 questions, 3 members)